Observed efficacy in switch subset at ≥96 weeks1,2
DESCOVY FOR PrEP® was noninferior to FTC/TDF
DESCOVY® (n=459)
OF PATIENTS WHO SWITCHED
FTC/TDF (n=438)
OF PATIENTS WHO CONTINUED
REMAINED HIV NEGATIVE
AT PRIMARY ANALYSIS AND ≥96 WEEKS
- Patients who switched: Patients who were using FTC/TDF at baseline and randomized to DESCOVY FOR PrEP
- Patients who continued: Patients using FTC/TDF at baseline who were randomized to continue using FTC/TDF
FTC/TDF=emtricitabine/tenofovir disoproxil fumarate.